Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines
XBB.1.5 infection was a suitable proxy to predict the neutralisation response following XBB-lineage vaccination. Our findings may support future vaccine development and vaccination strategies.
Authors
- Ana Atti
- Kelly Thomas
- Victoria Hall (ORCID: https://orcid.org/0000-0001-8744-4277)
- Sue Charlton (ORCID: https://orcid.org/0000-0002-0242-8524)
- Susan Hopkins (ORCID: https://orcid.org/0000-0001-5179-5702)
- Ashley Otter (ORCID: https://orcid.org/0000-0002-8317-9194)
- Bassam Hallis
- Anna England
- Julia Sung
- Jasmin Islam
- Sarah Foulkes
Institutions
- European Medicines Agency (NL)
- National Security Agency (US)
- Environment Agency (GB)
- Public Health England (GB)
Publication Details
- Journal
- Vaccine
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126898
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Health and Social Care